UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 30, 2018
Apellis Pharmaceuticals, Inc.
(Exact Name of Registrant as Specified in its Charter)
| Delaware | 001-38276 | 27-1537290 | ||
| (State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) | ||
| 6400 Westwind Way, Suite A Crestwood, KY |
40014 | |||
| (Address of Principal Executive Offices) | (Zip Code) | |||
Registrant’s telephone number, including area code: (520) 241-4114
Not applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers; Compensatory Arrangements of Certain Officers.
At a meeting of the Board of Directors (the “Board”) of Apellis Pharmaceuticals, Inc. (the “Company”) held on March 30, 2018, based on recommendations of the Compensation Committee, the Board approved annual base salaries for 2018 and target bonus percentages (as a percentage of annual base salary) for 2018 for each of the following executive officers of the Company, as set forth in the table below.
| Executive Officer |
Salary | Target Bonus | ||||||
| Cedric Francois, M.D., Ph.D., President and Chief Executive Officer |
$ | 555,000 | 55 | % | ||||
| Pascal Deschatelets, Ph.D. Chief Operating Officer |
400,000 | 45 | % | |||||
| Timothy Sullivan Chief Financial Officer |
380,000 | 40 | % | |||||
| David Watson General Counsel & Vice President of Corporate Development |
275,000 | 30 | % | |||||
Additional information regarding compensation of the Company’s executive officers will be included in the Company’s proxy statement to be filed in connection with its 2018 Annual Meeting of Stockholders to be held on June 4, 2018.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Apellis Pharmaceuticals, Inc. | ||||
| Date: April 2, 2018 | By: | /s/ Cedric Francois | ||
| Cedric Francois, M.D., Ph.D. | ||||
| President and Chief Executive Officer | ||||